{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T01:37:42Z","timestamp":1770082662205,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.clcc.2018.08.003","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T23:41:14Z","timestamp":1535067674000},"page":"e751-e761","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States"],"prefix":"10.1016","volume":"17","author":[{"given":"Sang Kyu","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel W.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0032-2988","authenticated-orcid":false,"given":"Afsaneh","family":"Barzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2018.08.003_bib1","first-page":"177","article-title":"Colorectal cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clcc.2018.08.003_bib2","author":"Union of International Cancer Control"},{"key":"10.1016\/j.clcc.2018.08.003_bib3","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","article-title":"Randomized trial of TAS-102 for refractory metastatic colorectal cancer","volume":"372","author":"Mayer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2018.08.003_bib4","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomized, placebo-controlled phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.clcc.2018.08.003_bib5","author":"The National Comprehensive Cancer Network"},{"key":"10.1016\/j.clcc.2018.08.003_bib6","author":"The National Comprehensive Cancer Network"},{"key":"10.1016\/j.clcc.2018.08.003_bib7","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1200\/JOP.2016.020339","article-title":"Exploration of the ASCO and ESMO value frameworks for antineoplastic drugs","volume":"13","author":"Becker","year":"2017","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clcc.2018.08.003_bib8","first-page":"e143","article-title":"Cost-effectiveness of trifluridine\/tipiracil for previously treated metastatic colorectal cancer in England and Wales","volume":"17","author":"Bullement","year":"2018","journal-title":"Clin Colorectal Cancer"},{"key":"10.1016\/j.clcc.2018.08.003_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3892\/mco.2016.1020","article-title":"Comparison of cost-effectiveness of regorafenib and trifluridine\/tipiracil combination tablet for treating advanced and recurrent colorectal cancer","volume":"5","author":"Kimura","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.clcc.2018.08.003_bib10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1634\/theoncologist.2017-0275","article-title":"Propensity score analysis of regorafenib versus trifluridine\/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study","volume":"23","author":"Moriwaki","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.clcc.2018.08.003_bib11","first-page":"4299","article-title":"Efficacy and safety of regorafenib and TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies","volume":"36","author":"Sueda","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.clcc.2018.08.003_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/(SICI)1099-1050(199905)8:3<257::AID-HEC427>3.0.CO;2-E","article-title":"A\u00a0Bayesian approach to stochastic cost-effectiveness analysis","volume":"8","author":"Briggs","year":"1999","journal-title":"Health Econ"},{"key":"10.1016\/j.clcc.2018.08.003_bib14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1017\/S0266462300105094","article-title":"The practice of discounting in economic evaluations of healthcare interventions","volume":"17","author":"Smith","year":"2001","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.clcc.2018.08.003_bib15","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/0002-9343(82)90786-0","article-title":"A\u00a0convenient approximation of life expectancy (the \u201cDEALE\u201d). I. Validation of the method","volume":"73","author":"Beck","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.clcc.2018.08.003_bib18","author":"United States Department of Labor. Bureau of Labor Statistics"},{"key":"10.1016\/j.clcc.2018.08.003_bib19","series-title":"Methods for the Economic Evaluation of Health Care Programmes, Fourth Edition","author":"Drummond","year":"2015"},{"key":"10.1016\/j.clcc.2018.08.003_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00044011-200727060-00002","article-title":"Economic burden of hematological adverse effects in cancer patients: a systematic review","volume":"27","author":"Liou","year":"2007","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clcc.2018.08.003_bib21","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Gruppo Italiano Malattie Ematologiche dell\u2019Adulto (GIMEMA) Infection Program. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2018.08.003_bib22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(15)70156-7","article-title":"Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"16","author":"Li","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clcc.2018.08.003_bib23","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014curious resilience of the $50,000 per QALY threshold","volume":"371","author":"Neuman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2018.08.003_bib24","unstructured":"James E, Trautman H, Szabo E, et\u00a0al. Comparative cost-efficiency analysis of granulocyte colony-stimulating factors for use in chemotherapy patients in the United States. Presented at the 59th American Society of Hematology Annual Meeting and Exposition; December 9-12, 2017; Atlanta, GA."},{"key":"10.1016\/j.clcc.2018.08.003_bib25","unstructured":"Bekaii-Saab T, Ou F, Ciombor K, et\u00a0al. Regorafenib Dose Optimization Study (ReDOS): a phase II randomized study of lower starting dose regorafenib compared to standard dose regorafenib in patients with refractory metastatic colorectal cancer. Presented at Gastrointestinal Cancers Symposium; January 18-20, 2018; San Francisco, CA."}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818301671?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002818301671?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:04:48Z","timestamp":1761519888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002818301671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["S1533002818301671"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2018.08.003","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2018.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}